CORRECTION article

Front. Pharmacol., 28 April 2022

Sec. Cardiovascular and Smooth Muscle Pharmacology

Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.910421

Corrigendum: Propofol Protects Myocardium From Ischemia/Reperfusion Injury by Inhibiting Ferroptosis Through the AKT/p53 Signaling Pathway

  • 1. Department of Anesthesiology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China

  • 2. Department of Anesthesiology, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China

  • 3. Department of Physiology, School of Basic Medical Science, Cheeloo College of Medicine, Shandong University, Jinan, China

Article metrics

View details

4

Citations

1,3k

Views

1k

Downloads

In the published article, there was an error regarding the affiliation for Jingxin Li. The full designation for affiliation 3 is “Department of Physiology, School of Basic Medical Science, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China”.

There was an error in the Funding statement. The correct name for the third listed funder is “Key Research and Development Program of Shandong Province (No. 2018GSF118079)”.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

Akt, ferroptosis, heart, ischemia/reperfusion injury, propofol, p53

Citation

Li S, Lei Z, Yang X, Zhao M, Hou Y, Wang D, Tang S, Li J and Yu J (2022) Corrigendum: Propofol Protects Myocardium From Ischemia/Reperfusion Injury by Inhibiting Ferroptosis Through the AKT/p53 Signaling Pathway. Front. Pharmacol. 13:910421. doi: 10.3389/fphar.2022.910421

Received

01 April 2022

Accepted

12 April 2022

Published

28 April 2022

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

13 - 2022

Updates

Copyright

*Correspondence: Jingxin Li, ; Jingui Yu,

This article was submitted to Cardiovascular and Smooth Muscle Pharmacology, a section of the journal Frontiers in Pharmacology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics